GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Days Sales Outstanding

Neuraxis (Neuraxis) Days Sales Outstanding : 11.56 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Days Sales Outstanding?

Neuraxis's average Accounts Receivable for the three months ended in Mar. 2024 was $0.08 Mil. Neuraxis's Revenue for the three months ended in Mar. 2024 was $0.65 Mil. Hence, Neuraxis's Days Sales Outstanding for the three months ended in Mar. 2024 was 11.56.

The historical rank and industry rank for Neuraxis's Days Sales Outstanding or its related term are showing as below:

NRXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.32   Med: 24.11   Max: 58.82
Current: 28.43

During the past 4 years, Neuraxis's highest Days Sales Outstanding was 58.82. The lowest was 18.32. And the median was 24.11.

NRXS's Days Sales Outstanding is ranked better than
86.52% of 890 companies
in the Biotechnology industry
Industry Median: 72.665 vs NRXS: 28.43

Neuraxis's Days Sales Outstanding declined from Mar. 2023 (30.44) to Mar. 2024 (11.56).


Neuraxis Days Sales Outstanding Historical Data

The historical data trend for Neuraxis's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Days Sales Outstanding Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
58.82 28.57 19.64 18.32

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.44 42.38 35.29 17.61 11.56

Competitive Comparison of Neuraxis's Days Sales Outstanding

For the Biotechnology subindustry, Neuraxis's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Neuraxis's Days Sales Outstanding falls into.



Neuraxis Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Neuraxis's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0.174 + 0.073) / 2 ) / 2.46*365
=0.1235 / 2.46*365
=18.32

Neuraxis's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (0.073 + 0.091) / 2 ) / 0.647*365 / 4
=0.082 / 0.647*365 / 4
=11.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis  (AMEX:NRXS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Neuraxis Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Neuraxis's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042